Medivir´s phase II study of MIV-711 in patients with osteoarthritis published in Annals of Internal Medicine
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected journal Annals of Internal Medicine (DOI: 10.7326/M19-0675). The title of the article is "Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis", author; P.G Conaghan et al. In the same issue there is an editorial by J.N Katz, MD, Msc, with the title; "Structural Modification in Osteoarthritis: Dawn of a New Day", (DOI: 10.7326/M19-3809), where the study results are discussed. Dr. Katz mentions the